• Home
  • NEW DAY MEDICINE
  • 8 (82) 2025
  • 73 -8 (82) 2025 - Boboraximova U.M. - INFLUENCE OF COMBINED ORAL CONTRACEPTION ON COMPONENTS OF METABOLIC SYNDROME IN WOMEN OF REPRODUCTIVE AGE

73 -8 (82) 2025 - Boboraximova U.M. - INFLUENCE OF COMBINED ORAL CONTRACEPTION ON COMPONENTS OF METABOLIC SYNDROME IN WOMEN OF REPRODUCTIVE AGE

INFLUENCE OF COMBINED ORAL CONTRACEPTION ON COMPONENTS OF METABOLIC SYNDROME IN WOMEN OF REPRODUCTIVE AGE

Boboraximova U.M. - Samarkand State Medical University

Resume

Objective: To assess the impact of combined oral contraceptives (COCs) on the components of metabolic syndrome in women of reproductive age. Study material. The study included 150 women aged 18 to 35 years, divided into two groups: Main group (n=80) – patients using COCs for at least 6 months; Control group (n=40) – women not using hormonal contraception. Each participant was individually assigned a contraceptive method, taking into account their health status, contraindications and personal preferences. All participants underwent a comprehensive examination, including: Measurement of blood pressure; Determination of body mass index (BMI) and waist circumference; Biochemical blood test to determine the level of glucose, triglycerides, high-density lipoprotein cholesterol (HDL and LDL); The effectiveness of the method, the frequency of side effects, patient compliance, and the impact on the course of the underlying disease were monitored over a 12-month period. Statistical data processing was performed using descriptive and comparative statistics. Calculation of insulin resistance indicators (HOMA-IR). Results. The general condition, occurrence of side effects and effectiveness of hormonal contraception were studied in the dynamics of observation. Conclusions. The correct choice of an effective and safe contraceptive in women with excess body weight has a positive effect on the body.

Key words: Obesity, fertility, metabolic risk, contraindications to contraception, risk assessment, medical eligibility criteria (MEC, WHO)

First page

419

Last page

424

For citation:Boboraximova U.M. - INFLUENCE OF COMBINED ORAL CONTRACEPTION ON COMPONENTS OF METABOLIC SYNDROME IN WOMEN OF REPRODUCTIVE AGE//New Day in Medicine 8(82)2025 419-424 https://newdayworldmedicine.com/en/new_day_medicine/8-82-2025

List of References

  1. Закон Республики Узблекистан «Об охране репродуктивного здоровья граждан», 12.03.2019
  2. Абдуллаева Л.М., Агабабян Л.P., Бобоpахимова У. Гормональная контрацепция - пpеимущества и недостатки.
  3. Абдуллаева Л.М., Агабабян Л.Р., Боборахимова У., Избыток массы тела у женщин репродуктивного возраста и методы его коррекции.
  4. Абдуллаева Л. М., Боборахимова У.М., Агабабян Л.Р. Программа расчета приемлемости комбинированной оральной контрацепции у женщин с ожирением
  5. Агентство по интеллектуальной собственности Республики Узбекистан уведомляет о факте поступления документов заявки на регистрацию программы для ЭВМ “Программа расчета приемлемости комбинированной оральной контрацепции у женщин с ожирением”
  6. Аметов А.С. Эффективное лечение ожирения – путь борьбы с эпидемией diabetusmellipidus. Медицинский совет. 2013; 2(2): 78-84.
  7. Ашурова Н.Г., Хамдамова М.Т. Ожирение – как фактор риска беременности и родов. Сборник материалов республиканской научно-практической конференции, 2-3 декабрь, 2015, Бухара, с.21
  8. Доклад о ситуации в области неинфекционных заболеваний в мире. ВОЗ; 2010.
  9. Прилепская В.Н., Межевитинова Е.А., Сасунова Р.А., Иванова Е.В., Летуновская А.Б., Набиева К.Р. Результаты клинического применения препарата, содержащего дроспиренон, у женщин с тяжелой формой предменструального синдрома. Акушерство и гинекология. 2012;2:81-5.
  10. A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel / J.M. Foidart, W. Wuttke, G.M. Bouw et al. // Eur. J. Contracept. Reprod. Health Care, 2000;5(2):124-134.
  11. CaprioМ., A. AntelmiА. «Antiaadipogenic effect of Drospirenone: potential implications for the treatment of metabolic syndrom» 2011.
  12. CaprioМ., AntelmiА. Antiaadipogenic effect of the Mineralocorticoid Receptor Antagonist Drospirenon: Potential Implications for the Treatment of Metabolic Syndrome // Endocrinology, July 01, 2015, ISSN 1945-7170
  13. Conway G. S., Dewailly D., DiamantiKandarakis E., Escobar-Morreale H. F. et al. The polycystic ovary syndrome: an endocrinological perspective from the European Society of Endocrinology // Eur. J. Endocrinol. 2014;171(4):1-29.
  14. Efficacy and safety of a low-dose combined oral contraceptive containing drospirenone 3 mg and ethinylestradiol 20 mcg in a 24/4-day regimen / L. Herndi, J. Marr, D. Trummer et al. // Contraception, 2009;80(1):18-24.

    file

    download